Pharmaceutical intermediates
Lumateperone Tosylate Intermediates
4 pharmaceutical intermediates for Lumateperone Tosylate. Indication: Schizophrenia; Depressive Disorder, Major, Depression.
About Lumateperone Tosylate
- Originator
- Bristol Myers Squibb
- Indication
- Schizophrenia; Depressive Disorder, Major, Depression
- Approved Date
- 04/22/2022
- DS/DP
- 03/12/2029
Available intermediates
4 intermediates currently listed for Lumateperone Tosylate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (4aS,9bR)-Ethyl 6-bromo-5-(2-(methylamino)-2-oxoethyl)-3,4,4a,5-tetrahydro-1H-pyrido[4,3-b]indole-2(9bH)-carboxylate | 2098497-32-4 | / | / |
| (4aS,9bR)-6-bromo-1H,2H,3H,4H,4aH,5H,9bH-pyrido[4,3-b]indole,(2S)-2-hydroxy-2-phenylacetic acid | 1059630-13-5 | / | / |
| (6bR,10aS)-3-Methyl-2,3,6b,7,8,9,10,10a-octahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline | 313368-85-3 | / | / |
| Ethyl2-oxo-2,3,9,10-tetrahydro-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline-8(7H)-carboxylate | 313544-31-9 | / | / |
Building toward Lumateperone Tosylate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →